Indian generic drugmakers face new U.S. tariff schedule with 2-year zero duty from Aug. 1, 2026
AI Market Summary
Trump outlined a stepped tariff regime for generic drugs imported into the US starting Aug 1, 2026: 0% for two years, then 100% for one year, and 200% thereafter to incentivize domestic manufacturing. Large Indian exporters (Aurobindo, Sun Pharma, Lupin, Zydus) with 30–46%+ revenue exposure to the US face higher medium-term trade-policy uncertainty, potentially pressuring cross-border pharma supply chains.
Impact level
● Medium
Affected assets
NCCOGOLD2USD/USDT+1.80%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
U.S. President Donald Trump said imported generic drugs will face a tiered tariff schedule starting Aug. 1, 2026, beginning with a two-year zero-rate period. He added the duty would rise to 100% in the third year and 200% from the fourth year onward to encourage manufacturers to shift generic drug production to the United States. The move directly affects Indian exporters such as Aurobindo Pharma and Sun Pharma, where U.S. shipments make up more than 30%–46% of FY26 revenue.
